Vancouver, British Columbia (PRWEB) July 20, 2011
Vitalwave™ is pleased to congratulate Dr. Bryon Bhagwandin on the publication of his abstract, “The Use of Antimicrobial Photodynamic Therapy for Prevention of HIV Transmission from Mother–to-Child: A Novel Approach.” This study will be presented at the International Aids Society (IAS) 6th Conference on HIV Pathogenesis, Treatment & Prevention which will take place in Rome, Italy from July 17th-20th.
A higher vaginal HIV viral load has been independently associated with a higher risk of transmission. This study evaluated the use of antimicrobial Photodynamic Therapy (aPDT), also known as Photodisinfection, as a means to reduce the vaginal viral load of pregnant women infected with HIV/AIDS. In 2008, more than 1.4 million pregnant women were living with this disease. An additional 430,000 children had been infected through mother-to-child transmission.
“The inclusion of the abstract in this year’s IAS Conference is an important accomplishment as it highlights the need to develop new approaches in preventing mother-to-child HIV transmission,” said Dr. Bryon Bhagwandin. “The use of aPDT to disinfect the birth canal is a novel approach that can bypass the stigma associated with HIV treatment and any reliance on patient compliance. I look forward to presenting my research at the IAS.”
More than 90% of children living with HIV in developing countries were infected through their mothers, and many are left without regular access to effective prophylaxis such as antiretroviral medication. Innovative approaches are therefore needed to address this problem. Vitalwave™ is the application of antimicrobial Photodynamic Therapy to the birth canal and is designed to destroy a variety of pathogens, including HIV. Currently under development, Vitalwave will be an in-clinic, low cost, and easy to administer procedure for use in the third world.
The following abstract will be presented at the IAS.
Use of Antimicrobial Photodynamic Therapy for Prevention of HIV Transmission from Mother to Child: A Novel Approach. B. Bhagwandin et al.,OrGenX Biopharma Inc
Vitalwave™ is a therapy that is under development for the prevention of mother-to-child transmission of pathogens, such as HIV. Vitalwave™ is being developed by OrGenX Biopharma Corporation.